Featured
Featured Videos
As AGBT comes to a close, Julianna LeMieux, PhD, Deputy Editor in Chief at GEN, chatted with Kevin Davies, PhD, GEN‘s Editor at Large, about some of the biggest announcements from the last day. They discuss how single-cell projects are getting bigger, a new 3D spatial company, NEB’s longevity in biotech and focus on sustainability, and Bruker’s deep dive into spatial.
Lastly, if you want more AGBT coverage, please join Julianna’s upcoming GEN Live show entitled, “AGBT Debrief: What’s Happening in NGS and Multiomics?” Experts from the NGS, single cell, and spatial fields join the show to review and dissect this year’s announcements and parse the promises made by companies. There will be a live Q&A session with the audience, so bring your questions for our panel. It’s on Friday, February 28 at noon and it’s free! You can register here.
More AGBT Video Coverage
The Sun Sets on AGBT 2025: Final Report from Marco Island
As the second day of AGBT came to a close, Julianna LeMieux, PhD, Deputy Editor in Chief at GEN, chatted with Kevin Davies, PhD, GEN‘s Editorial Director, about some of the biggest announcements from the day.
Next-generation sequencing (NGS) created the most excitement on day two, with lunch talks by both Roche and Ultima Genomics.
Ultima, a relative newcomer to the field, emphasized that they are driving big projects: single cell with the Billion Cells Project (with Chan Zuckerberg Initiative (CZI) and 10x Genomics) and the world’s largest and most comprehensive proteomics study to date (together with Olink and the UK biobank.)
Roche generated buzz last week when it first unveiled its new technology and instrument during a webinar. More information has been shared since then, with the posting of a preprint on bioRxiv and presenting customer data during their lunch talk at the meeting.
For more of AGBT coverage watch Dr. LeMieux’s first day recap and a her final report.
AGBT 2025: A Video Update from Day Two
Similar to March’s familiar evolution (in like a lion, out like a lamb) the feature stories in the March issue of GEN magazine highlight multiple fields that are evolving to develop better therapies. For example, although mRNA vaccines made front page headlines during the COVID-19 pandemic, companies are currently issuing in a new era of the technology to tackle some of the world’s most challenging bacterial pathogens including antibiotic-resistant gonorrhea. In addition, a deep dive into the rapidly evolving field of protein degradation-based therapies highlights the newer generations of proteolysis-targeting chimeras (PROTACs) and molecular glue degraders. In addition, the magazine includes stories about the latest genome editing techniques that transfer large DNA cargos and expanding microbe-based therapies beyond the gut. Lastly, the issue includes an A-list on the Top 10 Life Science Jobs Through 2033. Eight of the top 10 occupations show projected year-over-year increases in job openings over the next decade, according to the U.S. Bureau of Labor Statistics. Check out the list to learn more.
